UPL Ltd

- No explicit mention of any new fundraising through debt or equity in the provided transcript. - The company has significantly reduced its debt over the past four years, lowering net Debt-to-EBITDA from 4.2x to 1.5x and expresses comfort at these levels. - Management plans to use generated cash for debt repayment and capex, not indicating new debt raising. - Capex guidance is approx. $350 million for the year, funded through internal cash flows. - No written exit arrangements mentioned with private equity investors; current PE investments are plain vanilla equity. - Debt profile characterized by low cost, mostly unsecured, long tenure, with full prepayment flexibility. - Current statements suggest focus on deleveraging and investing internally rather than raising new funds.

- Total capex guidance for the year is approximately $350 million. - Around $160 million is allocated for manufacturing facilities. - The remaining capex primarily targets intangible assets, mainly within the global crop protection business. - Approximately $20 million capex is planned for Advanta Enterprises. - The company continues to invest in robust R&D infrastructure, with over 30 global facilities and 1,000+ employees driving innovation. - Plans to add another 10-15 production centers over the next 3-4 years to enhance production and distribution capabilities. - Strategic focus on accelerating growth in key emerging markets with differentiated and sustainable products. - Investment aligned with medium-term growth pillars including smart R&D and expanding new product portfolios valued at $2.5 billion between FY22 and FY27.

- FY24 revenue growth expected at 6-10% (Page 37). - EBITDA growth for FY24 projected at 8-12% (Page 37). - ROCE anticipated to improve by 125 to 175 bps to about 16.5-17% in FY24 (Page 37). - Post patent segment volume growth expected alongside launching new products generating over $120 million revenue (Page 55). - Growth drivers include differentiated, sustainable product portfolio expansion and ramp-up of innovative products (Pages 14, 15). - Advanta segment anticipates 11-15% revenue growth and 14-18% EBITDA growth, driven by new product launches and market share gains in multiple geographies (Pages 33, 23). - Expansion planned in key emerging markets and increasing differentiated and sustainable product revenue to 50% by FY27 (Page 15). - No capacity idling anticipated; aggressive competition expected to drive volume growth (Page 55). - Strong farm gate demand and biosolutions growth supporting outlook (Page 17).

- FY24 revenue growth guidance: 6-10% (Page 37, 17) - FY24 EBITDA growth guidance: 8-12% (Page 37, 60) - Crop protection business EBITDA growth: 14-18% (Page 60) - Nurture business expects loss reduction by half (Page 60) - ROCE expected to improve by 125-175 bps to about 16.5-17% in FY24 (Page 37) - Medium-term growth outlook through FY27 is positive with strong farm gate demand and ramp-up of innovative products (Page 17) - Innovation rate targeted to increase from 14% to 24% by FY27 (Page 15) - EPS largely flat year-on-year in the recent year but positive outlook through growth in differentiated and sustainable products (Page 12, 8) - Advanta platform showing 26% revenue growth and 29% EBITDA growth, expected to continue momentum (Page 33, 8)

The provided transcript from UPL’s FY23 Capital Markets Day does not explicitly mention the current or expected order book or pending orders figures. However, relevant insights include: - Inventories in the distribution channel are well positioned globally. - Distributors are generally aiming to de-inventory this year. - UPL did not overload products into inventories during supply chain concerns. - There is a strong focus on production planning and working closely with distributors/retailers. - Production adjustments have been made to manage inventory efficiently. - The company anticipates continued growth driven by new and sustainable product launches. - Market conditions include some delays in buying decisions due to pricing trends and seasonal factors. For specific order book or pending order values, no direct data is provided in this section of the document.